Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.43 |
| ▸ | NTRK3 | Q16288 | 3/20 | 0.43 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.43 |
| ▸ | KIT | P10721 | 2/20 | 0.42 |
| ▸ | RAF1 | P04049 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 7/20 | 0.41 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 3/20 | 0.40 |
| ▸ | CDK8 | P49336 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 3/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3763784 | 0.88 | KDR (0.47) | NTRK1NTRK3NTRK2KITRAF1 | |
| SCHEMBL9946550 | 0.85 | NTRK1 (0.39) | NTRK1NTRK3NTRK2KITRAF1 | |
| SCHEMBL9903084 | 0.83 | BRAF (0.58) | RAF1KDRBRAFEGFRRET | |
| SCHEMBL3767827 | 0.82 | CDK8 (0.50) | NTRK1NTRK3NTRK2KITKDR | |
| SCHEMBL3762266 | 0.82 | KIT (0.62) | NTRK1NTRK3NTRK2KITRAF1 | |
| SCHEMBL9903598 | 0.80 | BRAF (0.52) | NTRK1NTRK3NTRK2RAF1KDR | |
| SCHEMBL3768545 | 0.77 | BRAF (0.51) | NTRK1NTRK3NTRK2RAF1KDR | |
| SCHEMBL3762938 | 0.77 | RET (0.60) | NTRK1NTRK3NTRK2KITKDR | |
| SCHEMBL3836297 | 0.75 | RIPK1 (0.40) | NTRK1NTRK2KITRAF1KDR | |
| SCHEMBL3767943 | 0.75 | FLT3 (0.53) | NTRK1NTRK3NTRK2KDRBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1809629-B1 | N,N'-diphenyl urea derivatives suitable for the treatment of tumours, eye diseases, inflammation and diseases of the immune system | MERCK PATENT GMBH (DE) | 2012-06-13 | — | — | EP | claimed |
| US-7846927-B2 | N,N′-diphenylurea derivatives suitable as kinase inhibitors | MERCK PATENT GMBH (DE) | 2010-12-07 | — | — | US | disclosed |
| US-20070293488-A1 | tyrosine kinase inhibitors such as 1-(2-fluoro-5-trifluoromethylphenyl)-3-[4-(5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-4-ylamino)phenyl]urea, used as antitumor or anticarcinogenic agents or for the treatment of psoriasis, arthritis, retinopathy or dermatitis | MERCK PATENT GMBH (DE) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293488-A1 | tyrosine kinase inhibitors such as 1-(2-fluoro-5-trifluoromethylphenyl)-3-[4-(5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-4-ylamino)phenyl]urea, used as antitumor or anticarcinogenic agents or for the treatment of psoriasis, arthritis, retinopathy or dermatitis | TIE1, FLT1, FER | NTRK1 535/4885NTRK3 508/4885NTRK2 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.